title: [Diagnostic and therapeutic biomarkers for lung cancer patients].
abstract: Identification of sensitive biomarkers predictive of diagnosis, prognosis and drug sensitivity could have a clinically significant impact on non-small cell lung cancer (NSCLC) treatment strategies. Recently, molecular-targeted therapies have been developed for NSCLC treatment. NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. In addition, target therapies against echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein present in approximately 5% of the Japanese patients with adenocarcinomas are currently under development. In this paper, we reviewed diagnostic and therapeutic biomarkers for lung cancer patients.
authors.affiliation: Division of Pulmonary Medicine/Infection and Oncology, Department of Internal Medicine, Nippon Medical School.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Seike
authors.forename: Akihiko
authors.initials: A
authors.lastname: Gemma
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D066246:ErbB Receptors